Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for CNS diseases, with leading candidates roluperidone for schizophrenia and MIN-301 for Parkinson's. Established in 2014, the company also advances seltorexant for insomnia and MDD while employing nine full-time staff.
Minerva Neurosciences (NERV) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Minerva Neurosciences's actual EPS was -$1.09, missing the estimate of -$0.99 per share, resulting in a -10.17% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
